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Fenugreek (Trigonella foenum-graecum) is one of the oldest medicinal plants used 
worldwide to treat a variety of ailments, including hyperglycaemia. The seed and active 
compound – 4-hydroxyisoleucine (4-OH-lle) is thought to aid in the treatment of insulin 
resistance. This study investigated the effects of fenugreek aqueous seed extract and 4-OH-
lle, on human liver cells (HepG2) compared to insulin (100ng/ml) and metformin (2mM) 
controls. Cells were treated with fenugreek seed extract (FSE) and 4-OH-lle: 10 and 
100ng/ml under normogylcaemic (5mM glucose) and hyperglycaemic (30mM) conditions for 
72h. Tyrosine phosphorylation of insulin receptor-β (IR-β), protein kinase B (Akt) and 
glycogen synthase kinase-3α/β (GSK-3α/β) protein extracts was determined by western 
blotting. Gene expression of sterol regulatory element binding protein 1c (SREBP1c), 
glucose transporter 2 (GLUT2), glycogen synthase (GS) and glucokinase (GK) was evaluated 
by qPCR. Under normogylcaemic and hyperglycaemic conditions, FSE, 4-OH-lle and insulin 
at 100ng/ml and metformin (2mM) caused tyrosine phosphorylation of IR-β (p<0.0729; 
p<0.0121), Akt (p<0.0046; p<0.0005) and GSK-3α/β (p<0.0128; p<0.0048). However, FSE 
showed the greatest ability in positively controlling GS (*p<0.0262; *p<0.333) and GK 
(*p<0.333; *p<0.0213), which regulates glycogen synthesis. Also, FSE increased SREBP1c 
(*p<0.0157; *p<0.0012) which positively regulates GLUT2 (*p<0.0330, *p<0.0417), 
allowing glucose into the cell. The data suggests that FSE and 4-OH-lle causes an up-
regulation of insulin signaling proteins at a proximal level and related downstream gene 
expression. Taken together, the study suggests that FSE has potential application in the 
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According to statistics South Africa (SA), diabetes is one of the main causes of death in SA 
following human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) and tuberculosis (TB). The greatest increase in the incidence of diabetes is 
expected to be in Africa – it is predicted that the incidence of diabetes will have almost 
doubled by 2030 (WHO 2012). Latest reports on the prevalence of diabetes in SA read, “The 
diabetes tsunami is here. And we in SA are in trouble."  
Type 2 diabetes mellitus (T2DM) is a progressive, multifactorial metabolic disease - a main 
cause of morbidity and mortality related to non-communicable diseases worldwide (Bhat et 
al. 2005; Laffel 1999; Hotamisligil 2010). However many of these cases go undiagnosed as 
there are very few symptoms initially (Alberti et al. 2006). As the symptoms can be very mild 
and develop gradually, many people fail to recognize them as warning signs of diabetes 
(Alberti et al. 2006). Researchers estimate an average of 7 years for a person to be diagnosed 
with diabetes for the first time (Alberti et al. 2006). However by the time they are diagnosed, 
about 30% of people with T2DM have already developed complications which include; 
blindness, heart disease, stroke, amputations and kidney failure (Alberti et al. 2006; Leng et 
al. 2004; Meyer et al. 2002). In most cases these complications could have been avoided 
entirely by early diagnosis and proper treatment (Alberti et al. 2006). The fact that many 
diabetic patients only acquire help when they already have complications, also poses a great 
burden on the health care system, whereas 80% of T2DM could have been avoided by a 
healthy eating plan and regular exercise (Alberti et al. 2006). 
The main characteristic of T2DM is insulin resistance due to reduced expression and/or 
sensitivity of insulin receptors (IR) to insulin (Desvergne et al. 2006). This leads to a 
dysregulation of insulin mediated processes such as glucose uptake in muscle and fat, hepatic 
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glucose metabolism, glycogen synthesis and lipid metabolism (Gupta et al. 1995; Hazara et 
al., 1996). Insulin resistance is characterized by hyperglycaemia, where insulin is released 
from pancreatic beta cells, in response to elevated blood glucose levels (Bhat et al. 2005; 
Bhattacharya et al. 2007). Insulin binds IR, which is a tyrosine kinase that undergoes auto-
phosphorylation and catalyzes the phosphorylation of cellular proteins. Upon 
phosphorylation, these proteins interact with signaling molecules, resulting in a diverse series 
of signaling pathways (Cheatham and Kahn 2005). The molecular mechanisms underlying 
insulin resistance is linked to a disruption in the insulin signaling cascade (Desvergne et al. 
2006).  
At present, the treatment of T2DM mainly involves a sustained reduction in hyperglycaemia 
by the use of drugs such as metformin (de Souza et al. 2014). However, due to common 
unwanted side effects the efficacies of these compounds are debatable, resulting in a demand 
for new compounds for the treatment of diabetes (Bhat et al. 2005; Greyber et al. 2010). 
Therefore, plants have been suggested as a rich, but unexplored source of potentially useful 
anti-diabetic drugs (Bhat et al. 2005; Causevic-Ramosevac 2013). 
Trigonella foenum-graecum, commonly known as fenugreek, is a medicinal plant from the 
Papilionaceae, Leguminosae family and is native to Southern Europe and Asia (Belahcen et 
al. 2013). Fenugreek has been utilized as traditional medicine in countries such as North 
Africa, India and some parts of England (Belahcen et al. 2013). Documented medicinal 
benefits include reduced cholesterol levels and cardiovascular risk and controlled diabetes 
(Belahcen et al. 2013). The seeds of this plant are known to possess these medicinal 
properties (Tran 2003). Fenugreek seeds contain an unusual amino acid, 4-hydroxyisoleucine 
(4-OH-lle) - the biologically active compound exhibiting glucose–dependent insulin 
stimulating activity, hypoglycaemic and hypolipidaemic properties (Tran 2003; Broca et al. 
1999; Chempakam et al. 2008).  However no detailed study to elucidate the mechanism of 
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action of these extracts at the cellular and molecular level has been previously performed.    
In this study we investigated the effect of fenugreek seed extract (FSE) and 4-OH-lle on 
insulin signaling and subsequent gene expression in liver cells (HepG2) under 


















AIMS AND OBJECTIVES 
 
Aim: 
To determine the effects of FSE and 4-OH-lle - in comparison to insulin and metformin, on 
the insulin signaling pathway of HepG2 hepatoma cells. 
 
Objectives: 
1. To analyze the effects of FSE and 4-OH-lle on the insulin signalling pathway of human 
hepatoma cells. The study will focus on the proximal step in the cascade, which includes the 
tyrosine phosphorylation of IR-β as well as some of the more distal steps – tyrosine 
phosphorylation of Akt and GSK-3α/β.   
 
2. To evaluate the effect of FSE and 4-OH-lle on SREBP1c and GLUT2 expression relevant 
to glucose uptake of liver cells.   
 
3. To analyze the effects of FSE and 4-OH-lle on the expression of key genes – GS and GK 





1. LITERATURE REVIEW 
 
1.1 Introduction  
 
Plants are natural producers of medicinal compounds – which, when classified, has led to the 
discovery of new, inexpensive drugs with high therapeutic potential (Abubakar et al. 2013; 
Huie 2002). The exploitation of such medicinal compounds is very old, for example, in the 
Middle Ages in Europe, Achillea millefolium (yarrow tea) was taken to stop internal bleeding 
and to treat upper respiratory infections (Causevic-Ramosevac 2013).  Hippocrates prescribed 
Salix leaves to reduce fever, and garlic and onions were thought to have antibiotic properties 
and substances that lower blood sugar, serum cholesterol and blood pressure (Causevic-
Ramosevac 2013). Interestingly, salicin (an extract from the white willow tree), aided in anti-
inflammatory and pain-relieving properties and is now synthetically produced and used as a 
staple over-the-counter drug (Houghton and Raman 1998; Huie 2002). The leaves and seeds 
of Trigonella foenum-graecum (fenugreek) are not only used as a nutritional source but are 
also commonly prescribed in traditional medicine. Fenugreek is indigenous to Western Asia 
and Southern Europe but cultivated worldwide. In ancient times fenugreek was used by the 
Egyptians together with honey - for the treatment of rickets, diabetes, dyspepsia, rheumatism, 
anaemia and constipation. This plant has also been described in early Greek and Latin 
pharmacopoeias for hyperglycaemia and T2DM by Yemenite Jews, Indians and Chinese 




In rural areas, plants possessing medicinal properties are important in traditional medicine. 
Apart from the traditional healers practicing herbal medicine, there has been an increase in its 
demand and use with limited knowledge of side effects and therapeutic efficacy. The World 
Health Organization (WHO) estimated that 80% of the world’s population is dependent on 
medicinal plants for their primary health care (WHO 2008; Abdo et al. 2008; Mwaniki et al. 
2011; Gupta et al. 2010; Prakash and Sandhu 2012). Between 1983 and 1994 the United 
States Food and Drug Administration (FDA) approved 78% of the new drugs derived from 
unmodified natural products or semi-synthetic drugs obtained from natural sources (Mwaniki 
et al. 2011; Nepomuceno et al. 2006).  A survey was carried out on the usage of medicinal 
plants and revealed an increase from 3% (1993) to 37% (1998) (Briskin 2000). The low cost 
of herbal drugs has facilitated this shift in its increased usage accompanied by the developing 
world; the ‘green’ movement in the developed world that campaigns on the essential safety of 
natural products and the individualistic philosophy of western society that encourages self-
medication, with countless people choosing to treat themselves with herbal remedies (Sharma 
and Raghuram 1990; Houghton and Raman 1998).  
 
Trigonella foenum-graecum commonly known as fenugreek is a promising medicinal plant 
from the Papilionaceae, Leguminosae family (Belahcen et al. 2013). The seed of the plant is 
known to possess documented medicinal properties (Tran 2003). Fenugreek seeds contain an 
unusual amino acid, 4-hydroxyisoleucine (4-OH-lle) – which is a biologically active 
compound (Tran 2003; Broca et al. 1999; Chempakam et al. 2008). Medical uses of 
fenugreek in Indian and Chinese medicine, include labour induction, aiding digestion, and as 
a general tonic to improve metabolism and health. Preliminary studies have suggested 
possible hypoglycaemic and anti-hyperlipidaemic properties of fenugreek seed powder (Ara 
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et al. 2006). However, at this time, the evidence is insufficient to recommend fenugreek for 
or against the treatment of hyperglycaemia or hyperlipidaemia. 
1.2 The Trigonella foenum-graecum (fenugreek) plant 
 
Fenugreek is a self-pollinating annual leguminous bean. The seeds are sown in well-prepared 
soil which sprouts in three days. The seedling grows erect, semi-erect or branched based on 
its variety and attains a height of approximately 30 to 60cm (Chempakam et al. 2008). It has 
compound pinnate, trifoliate leaves, axillary white to yellow flowers, and 3-15cm long thin 
pointed hoop-like beaked pods (Causevic-Ramosevac 2013; Chempakam et al. 2008). Every 
pod contains 10-20 oblong greenish-brown seeds with unique hooplike groves (Chempakam 
et al. 2008; Basu and Sricjamroen 2010). Pods, number of seeds in a pod, seed shape-size and 
plant height varies from one fenugreek variety to another.  
 





1.3 The Trigonella foenum-graecum (fenugreek) seed 
 
Strongly aromatic and pungent flavoured fenugreek seeds are popular spices widely 
employed for their culinary as well as for medicinal properties. Fenugreek seeds are the most 
important and useful part of the fenugreek plant. These seeds are golden-yellow in colour, 
small in size, hard and have a four-faced stone like structure (Causevic-Ramosevac 2013; 
Basu and Sricjamroen 2010). The seed is 3-6mm long, 2-5mm wide and 2mm thick. They are 
a rich source of minerals, vitamins, and phytonutrients - a 100g of seeds provide 323 calories 
(Chempakam et al. 2008). They are also a good source of soluble dietary fiber – a 100g of 
seeds provide 24.6g or over 65% of dietary fiber (Chempakam et al. 2008). Non-starch 
polysaccharides (NSPs) which constitute major fiber content in the plant include saponins, 
hemicellulose, mucilage, tannin, and pectin (Chempakam et al. 2008). These compounds help 
lower blood low-density lipoprotein – cholesterol (LDL-C) levels by inhibiting bile salts re-
absorption in the colon. They also bind to toxins in food and help to protect the colon mucus 
membrane from cancers (Causevic-Ramosevac 2013; Chempakam et al. 2008). Non-starch 
polysaccharides increase the bulk of the food and augment bowel movements. Altogether, 
NSPs assist in smooth digestion and help relieve constipation ailments. It has been 
established that amino-acid – 4-OH-lle present in the fenugreek seeds has facilitator action on 
insulin secretion. The seeds contain fiber which aid in lowering the rate of glucose absorption 
in the intestines thus controls blood sugar levels. The seeds contain many phytochemical 
compounds such as choline, trigonelline, diosgenin, yamogenin, gitogenin, tigogenin and 
neotigogens (Causevic-Ramosevac 2013; Chempakam et al. 2008). Together, these 
compounds attribute for the medicinal properties of fenugreek. This spice is an excellent 
source of minerals like copper, potassium, calcium, iron, selenium, zinc, manganese, and 
magnesium (Causevic-Ramosevac 2013; Chempakam et al. 2008). Potassium is an important 
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component of cell and body fluids that help to control heart rate and blood pressure by 
countering action on sodium. Iron is essential for red blood cell production and as a co-factor 
for cytochrome-oxidases enzymes. It is also rich in many vital vitamins that are essential 
nutrients for optimum health, including thiamin, pyridoxine (vitamin B6), folic acid, 




Figure 2 Illustration of fenugreek seed (http://www.saraogiandco.com/fenugreek-
seeds.htm) 
1.4 Biologically active components of Trigonella foenum-graecum 
 
The composition of fenugreek includes a large number of chemical components. They 
include proteins and amino acids, flavonoids, saponins and steroidal saponins, coumarin, 
lipids, vitamins, minerals, galactomannan, fiber and alkaloids, such as trigonelline. Active 
compounds of fenugreek include soluble fiber, saponins, trigonelle, diosgenin and 4-OH-Ile 
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(Basch et al. 2003; Baquer et al. 2011). Hypoglycaemic activities have mainly been attributed 
to dietary fiber, saponin and 4-OH-Ile.  
The natural non-proteinogenic amino acid 4-OH-Ile possesses insulinotropic biological 
activity (Baissac et al. 1998; Broca et al. 1999). It is extracted from fenugreek seeds (Fowden 
et al. 1973) and its absolute stereo configuration was determined as (2S, 3R, 4S) (Alcock et 
al. 1989). 4-Hydroxyisoleucine increases glucose-induced release of insulin. In contrast to 
several types of pharmacological drugs that have been used for the treatment of type II 
diabetes (e.g. sulfonylureas), the insulin response mediated by 4-OH-lle is strictly dependent 
on the glucose concentration. This unique property of 4-OH-lle allows us to avoid 
undesirable side-effects such as hypoglycaemia in the therapy of type II diabetes (Bessler and 
Jackson 1981; Jennings et al. 1989). 4-Hydroxyisoleucine increases glucose-induced insulin 
release, in the concentration range of 100µmol/1 to 1mmol/1, through a direct effect on 
isolated islets of Langerhans from both rats and humans. The stimulating effect of 4-OH-lle is 
strictly glucose dependent; indeed, ineffective at low (3mmol/1) or basal (5mmol/1) glucose 
concentrations, the amino acid potentiates insulin secretion induced by supranormal (6.6 - 
16.7mmol/1) concentrations of glucose. In addition, in the isolated perfused rat pancreas, it 
was shown i) that the pattern of insulin secretion induced by 4-OH-lle was biphasic, ii) that 
this effect occurred in the absence of any change in pancreatic cell activity, and iii) that the 
more glucose concentration was increased, the more insulin response was amplified (Bhat et 
al. 2005; Li et al. 2005). Moreover, 4-OH-lle did not interact with other agonists of insulin 





Figure 3 Chemical structure of 4-hydroxyisoleucine 
(http://www.sigmaaldrich.com/catalog/product/sigma/50118?lang=en&region=ZA) 
1.5 Adverse effects and safety 
 
Although fenugreek has traditionally been considered safe and well-tolerated, some side 
effects have been associated with its use (Basch et al. 2003; Chiba et al. 2011). Patients using 
fenugreek, who are allergic to the plant or chickpeas, should take necessary caution due to 
possible cross reactivity (Bapat et al. 1997). The use of fenugreek during pregnancy and 
lactation or those with severe liver or kidney impairment should be avoided due to inadequate 
data suggesting use. Other reported side effects include transient diarrhoea, flatulence and 
dizziness, maple syrup urine, hypoglycaemia with large doses and decrease in blood urea to 
low normal after 12 weeks of ingestion of fenugreek seed powder (Abdel-Barry et al. 2000; 
Sharma and Raghuram 1990). Fenugreek can cause allergic reactions including nasal 
congestion, wheezing, persistent coughing, hoarseness, facial angioedema, and shock. 
Repeated topical application, chronic use and excessive ingestion of fenugreek should be 
avoided to prevent undesirable reactions or toxicities and due to long-term data being 
unavailable. Hypoglycaemia is an expected effect, and therefore, upon fenugreek 
supplementation care should be taken to monitor blood glucose levels (Abel et al. 1988; 
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Sharma and Raghuram 1990). Decrease in body weight has also been reported which has 
been attributed to a decrease in triiodothyronine (T3) (Kar et al. 1999). The data generated to 
date on the above in regard to fenugreek use in patients are sparse however future studies will 
lead to the development of well-designed, randomized, adequately powered clinical trials to 
evaluate the effect of fenugreek seed powder on measures of insulin resistance, insulin 
secretion and cholesterol metabolism.  
 
1.6 Pharmacological action of Trigonella foenum-graecum (fenugreek) 
 
Fenugreek has anti-diabetic and anti-lipidaemic effects. However, the exact mechanism of 
action is still unclear, as more work is needed. The anti-diabetic effect of fenugreek was 
thought to be due to formation of a colloidal-type suspension in the stomach and intestines 
when the mucilagenous fiber of the seeds is hydrated, therefore affecting gastrointestinal 
transit, slowing glucose absorption (Bhat et al. 2010). The anti-lipidaemic effects of 
fenugreek was thought to be due to inhibition of intestinal cholesterol absorption due to 
saponin-cholesterol complex formation, increased loss of bile through faecal excretion due to 
saponin-bile complexes, thus increasing conversion of cholesterol to bile by the liver, and 
effects of amino acid pattern of fenugreek on serum cholesterol (Enjoji et al. 2008; Au et al. 
2003). Fenugreek contains coumarins and other constituents that might affect platelet 
aggregation, but this might not be clinically significant (Au et al. 2003). Fenugreek 
constituents also show evidence of cardiotonic, diuretic, anti-inflammatory, anti-




1.6.1 Evidence based studies on the anti-diabetic properties of fenugreek 
 
The action of fenugreek on lowering blood glucose levels was said to be almost comparable 
to that of insulin, mimicking its effects (Baqueer et al. 2011).  Baqueer et al. (2011) and 
Ardekani et al. (2009) reported that the unusual amino acid, 4-OH-lle displays in vitro 
insulinotrophic activity and anti-diabetic properties in animal models. According to Ardekani 
et al. (2009), the amino acid is a useful and well-tolerated treatment for insulin resistance. It 
acts as a hypoglycaemic agent and a protective agent for the liver. A meta-analysis of the 
effect of herbs on glucose balance in type II diabetes patients, by Bar Dayan et al. (2011),  
and colleagues, stated that glycated hemoglobin (HbA1c) was significantly reduced in the 
group that used fenugreek as a food supplement (Bar Dayan et al. 2011). Further-more, it was 
reported by Prabhakar and Doble that ocular histopathological and biochemical abnormalities 
that are relevant to diabetic retinopathy were controlled when using fenugreek and sodium 
orthovandate alone or in low dose combination (Doble and Prabhakar 2011). A review article 
by Assad and Morse (2013) included three separate studies that assessed the effect of 
fenugreek in patients with diabetes. The first study assessed the effect of fenugreek use in 
patients with type 1 diabetes. This study showed a significant reduction of fasting blood 
glucose level, triglycerides; and total cholesterol, very-low-density lipoprotein (VLDL), and 
low-density lipoprotein (LDL) levels. Also, it showed an improvement of glucose tolerance 
test, and a reduction in 24h urinary glucose excretion (Assad and Morse 2013). The second 
study assessed the effect of fenugreek use (25g of fenugreek powder daily) in patients with 
T2DM. This study showed that fasting blood glucose level was reduced, and glucose 
tolerance was improved. Furthermore, there was a significant reduction in 24h urinary 
glucose excretion, and HbA1c after eight weeks of fenugreek intake (Assad and Morse 2013). 
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The third study showed that fenugreek improved glycaemic control, insulin sensitivity, and 
hypertriglyceridaemia in newly diagnosed patients with T2DM (Assad and Morse 2013). 
1.6.2 Evidence based studies on the anti – lipidaemic properties of fenugreek 
 
In the Hazra et al. (1996) trial on type 1 diabetes cited above, small but statistically 
significant reductions were noted in triglyceride (TG) (approximately 1.3 mMol/L; p<0.001) 
and low-density lipoprotein – cholesterol  (LDL-C) levels (approximately 1.0 mMol/L; 
p<0.01), but the level of high density lipoprotein cholesterol (HDL-C) remained unchanged. 
Without an adequate description of blinding and randomization, the results of this study can 
only be considered preliminary. Several case series have also found hypocholesterolemic 
effects associated with oral fenugreek. Hazra et al. (1996) investigated 15 non-obese, 
asymptomatic, hyperlipidemic adults. After the subjects had ingested 100g defatted fenugreek 
powder per day for three weeks, their TG and low-density lipoprotein – cholesterol (LDL-C) 
levels were lower than baseline values. Slight decreases in HDL levels were also noted. In a 
later study, normalization of lipid profiles was observed in 60 patients with T2DM whose 
diets were supplemented with 25g powdered fenugreek seeds per day for 24 weeks. While 
mean LDL-C, and TG levels decreased by 14-16 percent during the study period, mean HDL-
C levels increased by 10 percent. Similarly, Sowmya and Rajyalakshmi (1999) observed 
significant reductions in TG and LDL-C levels in 20 adults with hypercholesterolemia who 
received 12.5-18.0g powdered, germinated fenugreek seeds for one month, although no 
changes in HDL-C, very-low-density lipoprotein (VLDL), or TG levels were observed. In 
another study, Sharma et al. (1990) also reported a decrease in total cholesterol levels in 5 
diabetic patients treated with fenugreek seed powder (25g orally per day) for 21 days. Bordia 
et al., 1997 studied the effects of fenugreek seed powder (2.5g administered twice daily for 
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three months) in a subgroup of 40 subjects. In the subjects who had coronary artery disease 
and T2DM, significant decreases in the TG levels were observed, with no change in HDL-C 
level. The methodology for this study was not clearly documented. Most available studies are 
case series lacking proper controls, randomization, or blinding.  
1.7 Drug interactions 
 
Since fenugreek powder is rich in fiber, it can interfere with the absorption of oral 
medication. Prescription medicines should be taken separately from fenugreek-containing 
products. Simultaneous use of fenugreek with other hypoglycaemic agents might lower serum 
glucose level more than expected (Basch et al. 2003). Toxicological evaluation of diabetic 
patients taking fenugreek seed powder at a dose of 25g per day for 24 weeks showed no 
clinical hepatic or renal toxicity and no haematological abnormalities (Hazara et al. 1996). In 
an animal study, fenugreek powder failed to induce any signs of toxicity or mortality in mice 
and rats that received acute and sub-chronic regimes (Muralidhara et al. 1999). There were no 
significant haematological, hepatic or histopathological changes in weanling rats that were 
fed fenugreek seeds for 90 days (Rao et al. 1996). Simultaneous use of antiplatelet or 
anticoagulant drugs might increase the risk of bruising and bleeding because fenugreek 
constituents contain coumarins that have antiplatelet effects. Some drugs with anticoagulant 
or antiplatelet effects include aspirin, clopidrogel, non-steroidal anti-inflammatory drugs 
(NSAIDS) such as ibuprofen, diclofenac, naproxen, and others. Also, heparin, dalteparin and 
enoxaparin increase might increase the risk of bleeding. Simultaneous use of fenugreek and 
anti-diabetic agents including insulin, metformin, acarbose, glipizide, glyburide, pioglitazone, 
rosiglitazone, and others may cause hypoglycaemic episodes. Fenugreek can also interfere 
with corticosteroid drug activity, warfarin, and insulin, hormone therapy, monoamine oxidase 
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inhibitors, which may be due to high content of mucilagenous fiber in fenugreek and high 
viscosity in the gut (de Souza et al. 2014). 
1.8 Trigonella foenum-graecum (fenugreek) capsules 
 
Fenugreek seed capsules are readily available at pharmacies and health stores as over the 
counter complementary medicine. The directions for use include one to two capsules daily, or 
as prescribed. Each capsule contains 500mg of 100% pure Trigonella foenum-graecum seed. 
The indications include assistance in the stimulation of lactation, used for the treatment of 
dyspepsia, gastritis and diabetes and aids in the digestive process, treatment of high 
cholesterol and should only be used as directed by a health care practitioner. 
 
  







1.9 The liver – an organ involved in the metabolism of glucose 
1.9.1 Function of the liver 
 
Glucose is an essential nutrient for the human body. It is the main energy source for various 
cells, which depend on the bloodstream for a steady supply. Blood glucose levels, therefore, 
are carefully maintained. The liver plays an essential role in this process by balancing the 
uptake and storage of glucose via glycogenesis and the release of glucose via 
gluconeogenesis and glycogenolysis. The numerous substrate cycles in the major metabolic 
pathways of the liver play crucial roles in the regulation of glucose production (Jungermann 
and Keitzmann 1996). This includes the short- and long-term regulation of glucose-6-
phosphatase and its substrate cycle counter-part, GK (Francini et al. 2011). The substrate 
cycle enzyme glucose-6-phosphatase catalyzes the terminal step in both the gluconeogenic 
and glycogenolytic pathways and is opposed by the glycolytic enzyme GK (Francini et al. 
2011). In addition, the regulation of GLUT2, this facilitates the final step in the transport of 
glucose out of the liver and into the bloodstream (Ahn et al. 2005). 
1.9.2 Functional unit of the liver: the hepatocyte 
 
Hepatocytes are metabolic super-achievers in the body. They play critical roles in 
synthesizing molecules that are utilized elsewhere to support homeostasis, in converting 
molecules of one type to another, and in regulating energy balances (Berthiaume et al. 2003). 
To facilitate the exchange of a wide variety of substances between the blood and hepatocytes, 
the hepatocytes are directly exposed to the blood passing though the organ, by being in close 
contact with the liver blood sinusoids (Decker 1990). The sinusoids are lined by two types of 
cells - Kupffer cells and sinusoid lining cells (Decker, 1990). The blood enters through portal 
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tracts at the outer edge of the liver lobule, and filters through the sinusoids which are in close 
connection with the liver hepatocytes, until it reaches the central hepatic vein, where it drains 
away (Decker 1990). Thus the flow of blood is from the outside to the inside of the lobule. 
Under hormonal control, hepatocytes can respond to either feeding or fasting conditions by 
storing or producing glucose as necessary. In the fasting state, the effects of glucagon avoid 
hypoglycaemia by stimulating glucogenesis and glycogenolysis and initiating hepatic glucose 
release. In the post prandial state, insulin prevents hyperglycaemia, in part, by suppressing 
hepatic gluconeogenesis and glycogenolysis and facilitating hepatic glycogen synthesis. Both 
transcriptional regulation of rate limiting enzymes and modulation of enzyme activity 
through phosphorylation and allosteric regulation are involved (Guillou et al., 2008). 
1.9.3 Biochemical activity of liver cells 
1.9.3.1 Metabolism 
 
The hepatocytes of the liver are tasked with many of the important metabolic jobs that 
support the cells of the body. Because all of the blood leaving the digestive system passes 
through the hepatic portal vein, the liver is responsible for metabolizing carbohydrate, lipids, 
and proteins into biologically useful materials (Jungermann and Keitzmann 1996; Felig 
1975). 
 
The digestive system breaks down carbohydrates into the monosaccharide glucose, a primary 
energy source. Blood entering the liver through the hepatic portal vein is extremely rich in 
glucose from digested food (Jungermann and Keitzmann 1996). Hepatocytes absorb much of 
this glucose and store it as the macromolecule glycogen, a branched polysaccharide that 
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allows the hepatocytes to pack away large amounts of glucose and quickly release glucose 
between meals (Jungermann and Keitzmann 1996). The absorption and release of glucose by 
the hepatocytes helps to maintain homeostasis and protects the rest of the body from 
dangerous changes in the blood glucose level.  
 
Fatty acids in the blood passing through the liver are absorbed by hepatocytes and 
metabolized to produce energy in the form of ATP (Beylot et al. 2004). Glycerol (another 
lipid component) is converted into glucose by hepatocytes through the process of 
gluconeogenesis. Hepatocytes can also produce lipids like cholesterol, lipoproteins and 
phospholipids that are used by other cells throughout the body (Beylot et al. 2004). Much of 
the cholesterol produced by hepatocytes is excreted from the body as a component of bile 
(Beylot et al. 2004). 
 
Dietary proteins are broken down into their component amino acids by the digestive system 
before being passed on to the hepatic portal vein (Jungermann and Keitzmann 1996). Amino 
acids entering the liver require metabolic processing before they can be used as an energy 
source. Hepatocytes first remove the amine groups of the amino acids and convert them into 
ammonia and eventually urea (Jungermann and Keitzmann 1996). Urea is less toxic than 
ammonia and can be excreted in urine as a waste product of digestion. The remaining parts of 
the amino acids can be broken down into ATP or converted into new glucose molecules 





Figure 5 Role of the liver in metabolism 
(http://intranet.tdmu.edu.ua/data/kafedra/internal/chemistry/classes_stud/en/pharm/pr
ov_pharm/ptn/3/11.%20BIOCHEMICAL%20FUNCTION%20OF%20LIVER.htm) 
1.9.3.1.1 Carbohydrate metabolism 
 
Carbohydrate metabolism begins with digestion in the small intestine where monosaccharides 
are absorbed into the blood stream (Danielsson et al. 2005; DeFronzo et al. 1979). Blood 
sugar concentrations are controlled by insulin, glucagon and epinephrine. If the concentration 
of glucose in the blood is too high, insulin is secreted by the pancreas. Insulin stimulates the 
transfer of glucose into the cell, especially in the liver and muscle, although other organs are 
also able to metabolize glucose (Pandey and Srivastava 1998). 
 
In the liver and muscle, majority of the glucose is converted to glycogen by the process of 
glycogenesis (Jungermann and Keitzmann 1996). Glycogen is stored in the liver and muscle 
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until needed when glucose levels are low. When blood glucose levels are low, the hormones 
epinephrine and glucagon are secreted to stimulate the conversion of glycogen to glucose. 
This process is called glycogenolysis (Jungermann and Keitzmann 1996). If glucose is 
required immediately upon entering the cells to supply energy, it begins the metabolic 
process called glycolysis. The end products of glycolysis are pyruvic acid and ATP 
(Jungermann and Keitzmann 1996). Since glycolysis releases relatively little ATP, further 
reactions continue to convert pyruvic acid to acetyl CoA and enter the citric acid cycle to 
form citric acid (Jungermann and Keitzmann 1996). The majority of the ATP is made from 
oxidations in the citric acid cycle in connection with the electron transport chain (Jungermann 
and Keitzmann 1996). 
 
During strenuous muscular activity, pyruvic acid is converted into lactic acid rather than 
acetyl CoA (Jungermann and Keitzmann 1996). During the resting period, the lactic acid is 
converted back to pyruvic acid. The pyruvic acid in turn is converted back to glucose by the 
process called gluconeogenesis. If the glucose is not needed at that moment, it is converted 
into glycogen by glycogenesis (Jungermann and Keitzmann 1996).  
1.9.3.1.2 Fat metabolism 
 
The liver plays a central role in the whole body energy homeostasis by its ability to 
metabolize glucose and fatty acids. When energy intake is abundant, carbohydrates are used 
to generate ATP and surplus glucose (after replenishing glycogen stores) is converted to fatty 
acids - the process of lipogenesis. Fatty acids are used for the synthesis and storage of TG in 
white adipose tissue (Beylot et al. 2004). Although white adipose tissue functions essentially 
as an unlimited reservoir to accumulate TG, the liver is also able to store significant 
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quantities of lipids in conditions associated with prolonged excess energy consumption or 
impaired fatty acid metabolism manifesting as steatosis (Beylot et al. 2004). In fasted states, 
when glucose availability and insulin levels are low, there is a depletion of hepatic glycogen 
stores and a reduction in fatty acid production. Under these conditions, TGs stored in adipose 
tissues are hydrolyzed to free fatty acids and mobilized into plasma to reach the liver. In the 
liver, they undergo oxidation, converted to ketone bodies to be used as fuel by extrahepatic 
tissues (Beylot et al. 2004). 
 
Sources of increased TG content in hepatic steatosis include a) excess dietary TG associated 
with over-eating that reaches the liver as chylomicron particles from the intestine; b) 
increased TG synthesis in the liver from fatty acids formed from de novo lipogenesis; c) 
excess fatty acid influx into the liver from lipolysis of adipose tissue in obese and insulin-
resistant states and subsequent conversion to TG; d) diminished export of lipids from the liver 
in very-low-density lipoproteins; and e) reduced oxidation of fatty acids. High insulin 
suppresses hepatic glucose production, increases hepatic glucose uptake, and enhances 
lipogenesis in the liver (Reddy and Rao 2005; Beylot et al. 2004). In essence, perturbations 
affecting fatty acid influx into the liver, their de novo synthesis, and conversion to TG and/or 
oxidation to generate ATP contribute to disturbances in hepatic lipid homeostasis (Reddy and 
Rao 2005; Beylot et al. 2004; Garg and Simha 2006). 
 
De novo fatty acid synthesis in the liver is regulated by three known transcription factors: 
sterol regulatory binding protein 1c, Carbohydrate-responsive element-binding protein 
(ChREBP), and Peroxisome proliferator-activated receptor gamma (PPAR-γ) (Guillou et al. 
2008). Insulin and glucose concentrations regulate fatty acid synthesis in the liver. The 
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activation of genes responsible for lipogenesis in the liver by insulin is transcriptionally 
mediated by SREBP-1c (Guillou et al. 2008). These include fatty acid synthase and stearoyl-
CoA desaturase (Guillou et al. 2008; Quinn et al. 1983). A few aspects of lipid metabolism 
are unique to the liver, but many are carried out predominantly by the liver. Major examples 
of the role of the liver in fat metabolism include: 
 The liver is exceedingly active in oxidizing TGs to produce energy. The liver breaks 
down many more fatty acids than the hepatocytes require, and exports large quantities 
of acetoacetate into blood where it can be picked up and readily metabolized by other 
tissues (Reddy and Rao 2005; Beylot et al. 2004). 
 A bulk of the lipoproteins is synthesized in the liver. 
 The liver is the major site for converting excess carbohydrates and proteins into fatty 
acids and TGs, which are then exported and stored in adipose tissue. 
 The liver synthesizes large quantities of cholesterol and phospholipids. Some of this is 
packaged with lipoproteins and made available to the rest of the body. The remainder 
is excreted in bile as cholesterol or after conversion to bile acids (Reddy and Rao 
2005; Beylot et al. 2004). 
1.9.3.1.3 Protein Metabolism 
 
The most critical aspects of protein metabolism that occur in the liver are: 
 Deamination and transamination of amino acids, followed by conversion of the non-
nitrogenous part of those molecules to glucose or lipids. Several of the enzymes used 
in these pathways (such as, alanine and aspartate aminotransferases) are commonly 
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assayed in serum to assess liver damage (Jungermann and Keitzmann 1996; Tremblay 
et al. 2007). 
 Removal of ammonia from the body by synthesis of urea. Ammonia is very toxic and 
if not rapidly and efficiently removed from the circulation, will result in central 
nervous system disease (Jungermann and Keitzmann 1996).  
 Synthesis of non-essential amino acids. 
Hepatocytes are responsible for synthesis of most of the plasma proteins. Albumin, the major 
plasma protein, is synthesized almost exclusively by the liver. Also, the liver synthesizes 
many of the clotting factors necessary for blood coagulation (Jungermann and Keitzmann 






Figure 6 Overview of the metabolic function of the liver 
(www.elmhurst.edu/~chm/vchembook/600glycolysis.html) 
1.10 Insulin signaling pathway 
 
Insulin is a hormone released by pancreatic beta cells in response to elevated levels of 
nutrients in the blood. Insulin triggers the uptake of glucose, fatty acids and amino acids into 
liver, adipose tissue and muscle and promotes the storage of these nutrients in the form of 
glycogen, lipids and protein respectively. Failure to uptake and store nutrients results in 
diabetes. Type- I diabetes is characterized by the inability to synthesize insulin, whereas in 
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T2DM the body becomes resistant to the effects of insulin presumably because of defects in 
the insulin signaling pathway. 
 
The insulin receptor is composed of two extracellular alpha (α) subunits and two 
transmembrane beta (β) subunits linked together by disulphide bonds. Binding of insulin to 
the α subunit induces a conformational change resulting in the autophosphorylation of a 
number of tyrosine residues present in the β subunit (Johnston et al. 2001;  Arner et al. 1991; 
Hirosumi et al. 2002; Savage et al. 2005; Savage et al. 2007). These residues are recognized 
by phosphotyrosine-binding (PTB) domains of adaptor proteins such as members of the 
insulin receptor substrate family (IRS) (Kahn and Saltiel 2001; Alessi and Lizcano 2002). 
Receptor activation leads to the phosphorylation of key tyrosine residues on IRS proteins, 
some of which are recognized by the Src homology 2 (SH2) domain of the p85 regulatory 
subunit of PI-3-kinase (Shulman 2000). The catalytic subunit of PI-3-kinase - p110, then 
phosphorylates phosphatidylinositol (4, 5) bisphosphate (PtdIns (4, 5) P2) leading to the 
formation of Ptd (3, 4, 5) P3 (Nolan et al. 1994). A key downstream effector of Ptd (3, 4, 5) 
P3 is AKT which is recruited to the plasma membrane. Activation of AKT also requires the 
protein kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1), which leads to the 
phosphorylation of AKT (Lawlor and Alessi 2001). Once active, AKT enters the cytoplasm 
where it leads to the phosphorylation and inactivation of GSK-3α/β. A major substrate of 
GSK-3α/β is GS, an enzyme that catalyses the final step in glycogen synthesis. 
Phosphorylation of GS by GSK-3α/β inhibits glycogen synthesis; therefore the inactivation of 
GSK-3α/β by AKT promotes glucose storage as glycogen. Insulin stimulates glucose uptake 
in muscle and adipocytes via translocation of GLUT4 and in liver via GLUT2 vesicles to the 
plasma membrane. Glucose transporter4 translocation involves the PI3K/Akt pathway 
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(Carlson et al. 2003). And GLUT2 translocation involves activation of SREBP1c via insulin 
(Horton et al. 2002). 
In addition to promoting glucose storage, insulin inhibits the production and release of 
glucose by the liver by blocking gluconeogenesis and glycogenolysis (Kahn and Saltiel 2001; 
Samuel et al. 2010). Insulin directly controls the activities of a set of metabolic enzymes by 
phosphorylation and dephosphorylation events and also regulates the expression of genes 
encoding hepatic enzymes involved in gluconeogenesis. Recent evidence suggests that 
forkhead transcription factors, which are excluded from the nucleus following 
phosphorylation by AKT, play a role in hepatic enzyme regulation by insulin (Alessi et al. 
2000; Barthel et al. 2001). 
 
Insulin signaling also has growth and mitogenic effects, which are mostly mediated by the 
Akt cascade as well as by activation of the Ras/MAPK pathway (Pessin and Saltiel 2006). In 
addition, insulin signaling inhibits gluconeogenesis in the liver, through disruption of 
CREB/CBP/Torc2 binding. Insulin signaling also promotes fatty acid synthesis through 
activation of SREBP-1C. A negative feedback signal emanating from Akt/PKB, Protein 
kinase C, zeta (PKCδ), p70 S6K, and the MAPK cascades results in serine phosphorylation 




Figure 7: Activation of the insulin receptor evokes increased transcription of SREBP 
and the phosphorylation of members of the IRS family, SHC and Cbl. Upon tyrosine 
phosphorylation, these proteins interact with signaling molecules through their SH2 
domains, which results in the activation of a variety of signaling pathways, including PI 
3-kinase signaling, MAPK activation and the activation of the Cbl/CAP complex. These 








2. METHODS AND MATERIALS 
2.1 Materials 
 
Whole fenugreek seeds were purchased from a local herbal store. 4-hydroxyisoleucine 
(50118) was purchased from Sigma-Aldrich (Pty.) Ltd (Johannesburg, South Africa). The 
Hepg2 cell line was purchased from Highveld Biologicals (Johannesburg, South Africa). All 
other consumables were purchased from Merck unless otherwise stated.  
2.2 Preparation of Trigonella foenum-graecum 
 
Fenugreek seeds were prepared by grinding in a pestle and mortar and suspended in 
deionized water, then transferred into a conical tube and centrifuged (3 600 g, 10min) at room 
temperature (RT) (Bhandari et al. 2014). Supernatant (FSE) was removed, freeze dried and 
stored at 4
o
C. Fenugreek seed extract dilutions (10, 50 and 100ng/ml) were prepared using 
CCM. The total volume for each dilution was 5ml per a flask. For the hyperglycaemic 
treatment, CCM was supplemented with glucose to obtain a final concentration of 30mM. 4-
hydroxyisoleucine dilutions (10 and 100ng/ml) was also prepared using complete culture 
medium (CCM). 
2.3 Preparation of metformin  
 
Tablets containing 500mg of metformin were crushed with a pestle and mortar and suspended 
in 0.1M PBS. The stock solution was filter sterilized and used to prepare treatments (2mM) in 




2.4 Cell culture 
 
Human liver cells were cultured (37
o
C, 5% CO2) to confluency in 25cm
3
 flasks in CCM 
comprising Eagles minimum essential medium, 10% foetal calf serum, 1% L-glutamine and 
1% penstrepfungizone. Every second day, the flasks were rinsed three times with phosphate 
saline buffer (PBS) and fresh CCM (5ml), was added, to allow the cells to grow to 90% 
confluency. A confluent flask contains approximately a minimum of a million cells and more 
which is sufficient for treatment. The treatment period was 72 hours. 
2.5 Western blotting 
 
 




Western blotting is a sensitive assay for detective and characterization of proteins. This 
technique exploits the inherent specificity by polyclonal or monoclonal antibodies. It is an 
analytical method wherein a protein sample is electrophoresed on a sodium dodecyl sulphate 
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polyacrylamide gel electrophoresis (SDS-PAGE) and electro-transferred onto a nitrocellulose 
membrane. The transferred protein is detected using specific primary antibody and secondary 
enzyme labelled antibody and substrate. A protein sample is subjected to polyacrylamide gel 
electrophoresis. After this the gel is placed over a sheet of nitrocellulose and the protein in 
the gel is electrophoretically transferred to the nitrocellulose. The nitrocellulose is then 
soaked in blocking buffer to "block" the nonspecific binding of proteins. The nitrocellulose is 
then incubated with the specific antibody for the protein of interest. The nitrocellulose is then 
incubated with a second antibody, which is specific for the first antibody.  The membrane is 
then viewed via chemilluminescence. 
 
Figure 9: Apparatus utilized in western blotting (1 – Compact power supply, 2 – Plastic 
combs, 3 – Spacer glass plate, 4 – Glass plates,  5 – Glass plate holder, 6 – Sample 







2.5.2 Protein isolation 
 
HepG2 cells were grown to confluency in a 25cm
2
 conical flask and treated with 10, 50 and 
100ng/ml of fenugreek seed extract, 4-OH-lle, Insulin and metformin, over a period of 72h. 
The treatments were replenished every 24h (maintaining the same treatment concentrations 
previously used). At the end of the treatment period, the supernatants were removed and 
stored at -80
o
C  and the flasks were then rinsed twice with PBS. Cell lysis buffer (consisting 
of 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, 1 % 
phenoxylpolyethoxyethanol (Tritron X 100), 10 % glycerol, 50 mM sodium chloride (NaCl), 
protease inhibitor and phosphatase inhibitor) was then added to each flask and placed on ice 
for 10min. Protease and phosphatase inhibitor tablets had been previously added to the lysis 
buffer (1 tablet each/10ml of lysis buffer) to protect proteins against dephosphorylation. 
Specifically, protease inhibitor inhibits a broad spectrum of serine, cysteine, metalloproteases 
and calpains, while phosphatase inhibitor inhibits a broad spectrum of phosphatases such as 
acid, alkaline, serine/threonine and tyrosine protein phosphatase. After 10min, a scraper was 
used to remove the cells from each flask; the dislodged cells were pipetted into a 1ml tube, 
which was kept on ice. Tubes were then centrifuged at 4 °C and 10 000 rpm for 10 min. The 
supernatant containing protein from each sample was removed and placed into a new 1ml 
tube, and kept on ice. The remaining pellet was discarded. 
 
The crude protein extracts were quantified and standardised using the bicinchoninic acid 
(BCA) assay (Appendix A).  During this assay, all samples were kept on ice. Proteins and 
peptides do not absorb light in the visible region of the spectrum. However, when treated 
with an alkaline solution of cupric (Cu
2+
) tartrate complex, a purple colour develops due to 
the complexing of the Cu
2+
 ions by peptide bonds. This colour reaction is characteristic of the 
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biuret reaction in which a reduction of Cu
2+
 ion to cuprous (Cu
+
) ion by protein in an alkaline 
medium occurs. The Cu
+
 ion is then detected by a reaction with BCA to produce an intense 
purple colour that absorbs maximally at 562nm. The intensity of the colour produced is 
proportional to the number of peptides bonds participating in the reaction. 
 
Then, 120 μl of the supernatant were mixed with 30 μl of 5 x Laemmli buffer (25 nM Tris, 
pH 6.8, 2 % SDS, 0.002 % bromophenol blue, 10 % glycerol and 5 % 2-mercaptoethanol) 
prior to boiling at 100 ºC for 5 min, and briefly centrifuged to settle all the evaporation from 
the lid of the micro-centrifuge tube. The cell lysate was stored at -20 °C prior to use, or at -80 
°C for extended maintenance. 
 
 






2.5.3 Preparation of SDS-polyacrylamide gels  
 
The SDS-polyacrylamide gels (9cm x 6cm) were prepared in a multi gel casting chamber 
(Bio-Rad) according to manufacturer’s instructions. Each gel consisted of a 4% stacking gel 
(upper layer) (0.126M Tris, pH 6.8, 4% acrylamide/bis , 0.1% SDS, 0.05% ammonium 
persulphate (APS) and 0.1% N, N, N’, N’,-tetramethylethylenediamine (TEMED) and a 7.8% 
resolving gel (lower layer) (0.375M Tris, pH 8.8, 7.5% acrylamide/bis , 0.1% SDS, 0.05% 
APS and 0.05% TEMED). Firstly, smaller glass plate were placed in-front of the bigger one, 
the plates were levelled out on a flat surface and placed into the glass plate holder. The holder 
was then placed on a sponge, in the casting stand. The stacking gel was added which requires 
approximately 1hr to set followed by the resolving gel, which takes 20min to set. A comb is 
placed in the stacking gel to allow for the formation of 10-wells for sample loading. Once the 
gels are set, the gel must be removed from the glass plates by placing the plate under cool 
running water and a gel releaser was used to remove the smaller glass plate and then the gel. 






Figure 11: Apparatus utilized in the preparation of SDS polyacrylamide gels (1 – 
Sponges and 2 – gel releasers) (www.bio-rad.com/en-us/product/nucleic-acid-precast-
mini-format-electrophoresis-systems/mini-protean-tetra-cell) 
 
Figure 12: An example of the SDS polyacrylamide gel 
2.5.4 Electrophoresis 
 
The protein samples (25μl) and a molecular weight marker (Precision Plus Protein Dual 
Colour Standard, Bio-Rad) (10μl) were loaded into the wells of the gel. The four gels were 
clamped into the cassette and placed into the electrode tank (Bio-Rad) filled with running 
buffer (0.025M Tris, 0.192M glycine and 0.1% SDS). The samples were electrophoresed 
(150V, 1h) in 7.5% sodium dodecyl sulfate polyacrylamide gels using a Bio-Rad compact 






Figure 13: The process of electrophoresis in western blotting 
(http://stanxterm.aecom.yu.edu/wiki/index.php?page=SDS_PAGE, http://www.bio-
rad.com/en-us/sku/165-8004-mini-protean-tetra-cell-for-mini-precast-gels) 
2.5.5 Protein transfer 
 
Nitrocellulose membranes and fibre pads were soaked for 10min in transfer buffer (0.025M 
Tris, 0.192M glycine and 20% methanol). Following electrophoresis, the poly-acrylamide 
gels were placed in transfer buffer (10min) to equilibrate. The protein transfer sandwich was 
assembled with the gel placed on the nitrocellulose membrane in the middle of two fibre pads 
on either side as shown in Figure 14. The separated proteins were electro-transferred to a 










The membrane was incubated in a blocking solution of either 5% or 3% BSA in TTBS 
(0.150M NaCl, KCL, 0.05M Tris, 0.1% Tween 20, dH2O, pH 7.4) for 1h at room 
temperature. Thereafter, the membranes were immune-probed with a specific primary 
antibody (PY20, Akt and GSK-3α/β) at 4°C overnight. The membranes were then washed 
(5x, 10min) with TTBS and incubated (RT, 1h) with the respective horseradish peroxidase 
(HRP)-labelled secondary antibody to detect the primary antibody bound to the protein of 
interest. Lastly, membranes were washed (5x, 10min) with TTBS and then once rinsed with 
deionized water. Horse radish peroxidase (HRP) chemiluminescence detector and enhancer 
solution was used for the antigen-antibody complex and the signal was detected with the 
Alliance 2.7 image documentation system (UViTech). Expression of proteins was analyzed 
with UViBand Advanced Image Analysis software v12.14 (UViTech). Data was expressed as 
relative band density. To normalize the expression of the proteins; β-actin (CS1615), 1:2 000 
(used for GSK-3α/β); IR-β (CS3025) (used of PY20) and total Akt (CS9272) 1:1000 (used 
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for Akt) was assessed by quenching each membrane and following the same protocol as per 
the addition of the primary antibody. 
 
 






2.5.7 Re-probing of membranes 
 
The membrane was incubated with hydrogen peroxide solution (for stripping to block the 
HRP signals) for 30 min at 37 ºC, followed by washes (2x, 10min) and blocked for 1h with 




2.6 Quantitative-polymerase chain reaction  
2.6.1 Principle 
 
PCR is used to amplify a specific region of a DNA strand (the DNA target). PCR typically 
amplifies DNA fragments of between 0.1 and 10 kilo base pairs (kb), although some 
techniques allow for amplification of fragments up to 40kb in size.
 
The amount of amplified 
product is determined by the available substrates in the reaction, which become limiting as 
the reaction progresses. A basic PCR set up requires several components and reagents.
 
These 
components include: DNA template that contains the DNA region (target) to be amplified, 
two primers that are complementary to the 3' (three prime) ends of each of the sense and anti-
sense strand of the DNA target, Taq polymerase or another DNA polymerase with a 
temperature optimum at around 70 °C, deoxynucleoside triphosphates (dNTPs, sometimes 
called "deoxynucleotide triphosphates"; nucleotides containing triphosphate groups), the 
building-blocks from which the DNA polymerase synthesizes a new DNA strand, buffer 
solution, providing a suitable chemical environment for optimum activity and stability of the 
DNA polymerase, bivalent cations, magnesium or manganese ions; generally Mg
2+
 is used, 
but Mn
2+
 can be utilized for PCR-mediated DNA mutagenesis, as higher Mn
2+
 concentration 
increases the error rate during DNA synthesis and monovalent cation potassium ions. 
 
The PCR is commonly carried out in a reaction volume of 10–200μl in small reaction tubes 
(0.2–0.5ml volumes) in a thermal cycler. The thermal cycler heats and cools the reaction 
tubes to achieve the temperatures required at each step of the reaction. There are three 
defined steps in PCR: 1) denaturation, 2) annealing and 3) extension. Denaturation involves 
the separation, usually above 90°C, of double stranded (ds) DNA into two single stranded 
(ss) DNA template strands for accessibility of the target region. In the annealing step, the 
36 
 
temperature is dropped to allow for the hybridisation of oligonucleotide primers to 
complementary sites flanking the target region. Finally, extension entails the synthesis of 
DNA (addition of dNTPs) at the free 3’ hydroxyl end of the primers by thermostable Taq 
DNA polymerase. This cycle is repeated for 30-40 times, and the result is an exponential 
amplification of the target DNA. Many modern thermal cyclers make use of the Peltier effect, 
which permits both heating and cooling of the block holding the PCR tubes simply by 
reversing the electric current. Thin-walled reaction tubes permit favourable thermal 
conductivity to allow for rapid thermal equilibration. Most thermal cyclers have heated lids to 
prevent condensation at the top of the reaction tube. Older thermocyclers lacking a heated lid 
require a layer of oil on top of the reaction mixture or a ball of wax inside the tube. 
Quantitative-polymerase chain reaction is a technique that enables one to determine the 
amount of a target gene in a sample.  
 
RNA is first isolated from cells and then reverse transcribed to ss complementary (c) DNA. 
cDNA is then used as the starting material for Q-PCR. The cycling steps of Q-PCR are 
similar to conventional PCR. Quantification of DNA is made possible by including a DNA-
binding dye called SYBR Green in the reaction. SYBR Green binds to dsDNA amplicons 
proportionally and the fluorescence is detected after excitation. A curve is plotted with 
fluorescent emission over time from which the initial amount of DNA in each sample is 
obtained. A threshold is set at a constant point of exponential increase in the curves and the 
cycle time value for each sample is determined. Along with the gene of interest, samples are 
analysed for expression of a house keeping gene, and the amount of target DNA is reported 


















2.6.2 RNA Isolation 
 
The level of expression of messenger ribonucleic acid (mRNA) was determined by firstly 
isolating total ribonucleic acid (RNA) from cells treated in 25cm
3
 flasks. After the flasks 
were rinsed twice with PBS, 500µl Triazol and 500µl 0.1M PBS were added to the flasks 
(RT, 5min).  The cell lysate was removed from the flasks, transferred to 1.5ml tubes and 
incubated at -80˚C overnight. Following the overnight incubation, 100µl chloroform was 
added to each sample and centrifuged (12 000 g, 20min, 4˚C). Samples were then washed 
with 500µl of cold 75% ethanol. Afterwards, samples were centrifuged (7 400 g, 15min, 
4˚C), ethanol was removed and the pellet containing RNA was re-suspended in nuclease-free 
water. The RNA was quantified using a spectrophotometer (Nanodrop2000). All RNA 
samples were standardized to a concentration of 1500ng/µl. 
 
 




2.6.3 cDNA synthesis 
 
Standardized RNA was reverse transcribed by reverse transcriptase into copy 
deoxyribonuclease acid (cDNA) using Script II RT kit (Qiagen) according to the 
manufacturer’s instructions. The reaction was then subjected to 42°C (15min) and 95°C 
(5min) (GeneAmp® PCR System 9700, Applied Biosystems) to obtain cDNA. 
RNA was reverse transcribed to cDNA as per manufacturers’ guidelines using the RT2 First 
Strand Kit (SA Biosciences™). Firstly, genomic DNA elimination mixture (10μl) was 
prepared with 2μl (200ng) of total RNA, 2μl of 5X cDNA elimination buffer and 6μl of 
RNase-free water. Secondly, reverse transcriptase cocktail (10μl) was prepared with 4μl of 
reverse transcriptase buffer 3, 1μl of primer and external control mix, 2μl of reverse 
transcriptase enzyme mix and 3μl of RNase-free water. For the cDNA synthesis reaction, a 
20μl reaction containing 10μl each of genomic DNA elimination buffer and reverse 
transcriptase cocktail for each sample was prepared and subjected to incubation at 42°C 
(15min) followed by heating at 95°C (5min) (GeneAmp® PCR System 9700, Applied 
Biosciences). Subsequently, 80μl of RNase-free water was added to each reaction mixture 
and stored at -70°C for further use. 
 
 
Figure 18: The process of cDNA synthesis 
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2.6.4 Quantitative-polymerase chain reaction  
 
Quantitative PCR was used to determine mRNA expression using the iScript SYBR Green 
PCR kit (Qiagen). A reaction of 12.5μl was prepared consisting of 6.25μl IQ™ SYBR® 
green supermix (cat. no. 170–8880), 3.75μl nuclease free water, 1μl cDNA, and 0.75μl sense 
and anti-sense primer (10mM, inqaba biotec™) were used. The mRNA expression was 
compared and normalized to a housekeeping gene, β-Actin and 18S. The reaction was 
subjected to an initial denaturation (95°C, 10min), followed by 40 cycles of denaturation 
(95°C, 15s), annealing (specific temperatures)  and extension (72°C, 30s) (CFX and CFX 
analysis software) and mRNA expression was determined using the method described by 
Livak and Schmittgen (Livak et al., 2001) to calculate relative fold change. Primer sequences 
and annealing temperatures were as follows: SREBP1c– Sense 5’-GTGGCGGCTGCAT 
TGAGAGTGAAG-3’; SREBP1c– Antisense  5’-AGGTACCCGAGGGCATCCGAGAAT-
3’(58˚C); GLUT2- Sense 5’-GGAGTCCTGTCAATTCCAGG-3’; GLUT2– Antisense 5’- 
CAAGTCTAATCTTCTCAGCG-3’(56˚C); GS– Sense 5’- GAAAGCCAAGAAACTGT 
TGTGATG-3’; GS– Antisense 5’- GAGGACTGGAGGCCTGAGAC-3’(60˚C); GK– Sense 
5’-TCCACTTCAGAAGCCTACTG-3’; GK–Antisense 5’-TCAGATTCTGAGGCTCAAAC 
-3’(60˚C); β-Actin– Sense 5’-TGACGGGTCACCCACTGTGCCCAT-‘3 and β-Actin– 
Antisense 5’- CTAGAAGCATTTGCGGTGGACGATGGAGGG-‘3. 
 




2.7 Measurement of glucose concentration 
 








2.8 Statistical analysis 
 
Statistical analyses were performed using GraphPad Prism v5.0 software (Graph Pad 
Software Inc., La Jolla, USA). The data were expressed as relative fold change and the mean 
standard deviation of the samples in the experiments. Statistical comparisons were made 
using a ONE-WAY ANOVA, non-parametric test and a Dunn’s post test. The data were 








3.1 Western blotting 
 
To determine the effect of FSE, 4-OH-lle, insulin and metformin treatments on protein 
expression, the levels of IR-β, pAkt and pGSK-3α/β were assessed using western blot. The 
concentration of FSE and 4-OH-lle used for the treatments were determined from a range of 
concentrations including 0, 10, 50 and 100ng/ml (figure 21). The treatments included an 
untreated control (0ng/ml) and a treatment of 100ng/ml of FSE and 4-OH-lle coupled with 
the use of insulin (100ng/ml) and metformin (2mM) which served as positive controls. 
Western blotting experiment was performed twice 
 
 
Figure 21: Range of fenugreek seed (FSE) (10, 50, 100ng/ml), 4-hydroxyisoleucine (4-OH-
lle) (10, 50, 100ng/ml) treatment and control (0ng/ml) on phosphorylation of PY20, on 
HepG2 cells. A - Normoglycaemic conditions. B - Hyperglycaemic conditions. MW – 






FSE: Induced a significant 2.29-fold increase in PY20/IR-β expression (*p<0.0729); a 1.89-
fold increase in pAkt/total Akt expression (**p<0.0046) and a 1.73-fold increase in pGSK-
3α/β/total GSK-3αβ expression (*p<0.0128) (figure 22C, 23E, 24G). 
 
4-OH-lle: Induced a significant 2.91-fold increase in PY20/IR-β expression (*p<0.0729); a 
2.06-fold increase in pAkt/total Akt expression (**p<0.0046) and a 2.69-fold increase in 
pGSK-3α/β/total GSK-3αβ expression (*p<0.0128) (figure 22C, 23E, 24G).  
 
Insulin: Induced a significant 2.47-fold increase in PY20/IR-β expression (*p<0.0729); a 
2.09-fold increase in pAkt/total Akt expression (**p<0.0046) and a 2.57-fold increase in 
pGSK-3α/β/total GSK-3αβ expression (*p<0.0128) (figure 22C, 23E, 24G).  
 
Metformin: Induced a significant 1.57-fold increase in PY20/IR-β expression (*p<0.0729); a 
1.59-fold increase in pAkt/total Akt expression (**p<0.0046) and a 1.47-fold increase in 
pGSK-3α/β/total GSK-3αβ expression (*p<0.0128) (figure 22C, 23E, 23G).  
 
Hyperglycaemic conditions 
FSE: Induced a significant 1.83-fold increase in PY20/IR-β expression (*p<0.0121); a 2.32-
fold increase in pAkt/total Akt expression (***p<0.0005) and a 1.70-fold increase in pGSK-
3α/β/total GSK-3αβ expression (**p<0.0048) (figure 22 D, 23F, 24H). 
 
4-OH-lle: Induced a significant 1.84 -fold increase in PY20/IR-β expression (*p<0.0121); a 
2.42 -fold increase in pAkt/total Akt expression (***p<0.0005) and a 1.75 -fold increase in 
pGSK-3α/β/total GSK-3αβ expression (**p<0.0048) (figure 22D, 23F, 24H). 
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Insulin: Induced a significant 2.13 -fold increase in PY20/IR-β expression (*p<0.0121); a 
2.09 -fold increase in pAkt/total Akt expression (***p<0.0005) and a -fold increase in 
pGSK1.50 -3α/β/total GSK-3αβ expression (**p<0.0048) (figure 22D, 23F, 24H). 
 
Metformin: Induced a significant 1.34 -fold increase in PY20/IR-β expression (*p<0.0121); 
a 1.26 -fold increase in pAkt/total Akt expression (***p<0.0005) and a 2.50 -fold increase in 
pGSK-3α/β/total GSK-3αβ expression (**p<0.0048) (figure 22D, 23F, 24H). 
 
 
Figure 22: Fenugreek seed extract (FSE), 4-hydroxyisoleucine (4-OH-lle), metformin 
and insulin treatments on phosphorylation of IR-β, on HepG2 cells. C – Normal 







Figure 23: Fenugreek seed extract (FSE), 4-hydroxyisoleucine (4-OH-lle), metformin 
and insulin treatments on phosphorylation of Akt, on HepG2 cells. E – Normal 
conditions (**P<0.0046) and F – Hyperglycaemic conditions (***p<0.0005). 
 
 
Figure 24: Fenugreek seed extract (FSE), 4-hydroxyisoleucine (4-OH-lle), metformin 
and insulin treatments on phosphorylation of GSK-3α/β, on HepG2 cells.  G – Normal 
conditions (*P<0.0128) and H – Hyperglycaemic conditions (**p<0.0048).  
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3.2 Quantification of mRNA 
 
The mRNA expression of SREBP1c, GLUT2, GS and GK in HepG2 cells was determined 
using qPCR. The samples were run in triplicate. 
 
Normoglycaemic conditions 
SREBP1c: Fenugreek seed extract induced a significant 1.47-fold increase; 4-OH-lle a 5.08-
fold increase; insulin a 2.09-fold increase and metformin caused a significant 0.03-fold 
decrease in expression (*p<0.0157) (figure 25).  
 
GLUT2: Expression increased 3.79-fold by FSE; a 1.37-fold increase by 4-OH-lle; a 1.51-
fold increase by insulin and metformin reduced expression 0.9-fold (*p<0.0330) (figure 26).  
 
GS: Fenugreek seed extract induced a significant 1.37-fold increase and a 0.04-fold decrease 
by 4-OH-lle, 0.2-fold by insulin and 0.18-fold by metformin (*p<0.0262) (figure 27).  
 
GK: Increased expression 3.99-fold by FSE and decreased expression 0.19-fold by 4-OH-lle, 
0.86-fold by metformin and 0.23-fold by insulin (*p<0.345) (figure 28). 
 
Hyperglycaemic conditions 
SREBP1c: Expression was reduced by FSE 0.82-fold; 0.76-fold by 4-OH-lle; 0.19-fold by 
metformin and insulin increased expression 3.91-fold (**p<0.0012) (figure 25). 
 
GLUT2: Fenugreek seed extract caused an elevation of 9.87-fold; 2-fold by 4-OH-lle; 2.47-
fold by insulin and a 0.63-fold decrease by metformin (*p<0.0417) (figure 26). 
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GS: Expression was increased 2-fold by FSE and 1.07-fold by insulin and decreased 0.29-
fold by metformin and 0.5-fold by 4-OH-lle (*p<0.0333) (figure27). 
 
GK: Fenugreek seed extract caused an elevation of 23.92-fold; 2.11-fold by 4-OH-lle; 15.85-
fold by insulin and 3.35-fold by metformin (*p<0.0213) (figure 28). 
 
 
Figure 25: The effect of fenugreek seed extract (FSE), 4-hydroxyisolecuine (4-OH-lle) 
and insulin treatment on SREBP1c expression, on Hepg2 cells under normoglycaemic 

























Figure 26: The effect of fenugreek seed extract (FSE), 4-hydroxyisolecuine (4-OH-lle) 
and insulin treatment on GLUT2 expression, on Hepg2 cells under normoglycaemic 
(*p<0.0330) and hyperglycaemic conditions (*p<0.0417). 
 
 
Figure 27 The effect of fenugreek seed extract (FSE), 4-hydroxyisolecuine (4-OH-lle) 
and insulin treatment on GS expression, on Hepg2 cells under normoglycaemic 
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Figure 28 The effect of fenugreek seed extract (FSE), 4-hydroxyisolecuine (4-OH-lle) 
and insulin treatment on GK expression, on Hepg2 cells under normoglycaemic 



































Table 1 Supernatant glucose concentrations following fenugreek seed extract (FSE), 4-
hydroxyisoleucine (4-OH-lle), insulin and metformin treatment 
Normoglycaemic state Hyperglycaemic state 
Treatment (ng/ml) Glucose mMol/L) Treatment (ng/ml) Glucose (mMol/L) 
Control (0) 5.1 Control (0) >28 (read too high) 
Insulin (100) 1.9 Insulin (100) 18.0 
Metformin (100) 2.8 Metformin (100) 21.0 
FSE (100) < 1.7 (read too low) FSE (100) 19.5 






















Fenugreek has been reported to aid in the reduction of glucose concentrations during 
hyperglycaemic conditions. Previous studies have reported this glucose lowering effect 
owing to the seed, more specifically 4-OH-lle (Bhat et al. 2005; Breil et al. 2004). However 
these studies showed no cellular or metabolic action of the seed and amino acid in exerting 
their glucose lowering effect. Our study investigated the molecular effects of FSE and 4-OH-
lle on both proximal and distal insulin signaling proteins, entry of glucose into the cell and 
glycogen storage, in vitro.  
In the present study, the results revealed FSE, 4-OH-lle, insulin and metformin increased 
activation of IR-β (figure 21, 22). This activation is important in initiating the signal 
transduction of internal cellular mechanisms that directly affect glucose uptake (Cheatham 
and Kahn 2005). High circulating blood glucose triggers the release of insulin from 
pancreatic beta cells. Insulin binds to the extracellular alpha subunits of the insulin receptor.  
This causes a conformational change in the beta subunit, activating the kinase domain of the 
insulin receptor (Cheatham and Kahn 2005). In order of stimulation; metformin, FSE, insulin 
and 4-OH-lle, caused a significant elevation in tyrosine phosphorylation of IR-β (figure 21, 
22).  Activated kinase domain of IR-β is imperative in auto-phosphorylation of Akt via the 
phosphoinositide 3-kinase (PI3K) pathway (Kim et al. 1999; Lawler et al. 2001). Fenugreek 
seed extract displayed the most significant increase in tyrosine phosphorylation, following 
insulin, 4-OH-lle and metformin with the least effect (figure 23 E, F).  Phosphorylated Akt 
plays a critical role in regulating glycogen synthesis via the auto-phosphorylation of GSK-
3α/β (Cheatham and Kahn 2005). Phosphorylation of a protein such as GS by GSK-3α/β 
regularly inhibits the activity of its downstream target (Cheatham and Kahn 2005; Bhat et al., 
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2005). Therefore, when pAkt auto-phosphorylates GSK-3α/β, its activity is reduced. A 
reduction in GSK-3α/β activity loses its ability to inhibit GS, causing an increase in the active 
form of GS. Fenugreek seed extract, 4-OH-lle, insulin and metformin cause significant 
elevation in tyrosine phosphorylation of GSK-3α/β (figure 24 G, H). These findings correlate 
with the 1.37 (normoglycaemic) and 2.00 (hyperglycaemic) fold increase by FSE of GS 
(Figure 27). Insulin caused a 0.2 (normoglycaemic) fold decrease and 1.07 (hyperglycaemic) 
fold increase in GS expression. However, 4-OH-lle and metformin caused a decrease in 
expression of GS (Figure 27). Glycogen is a polysaccharide that is the principal storage form 
of glucose. Glycogen is not as reduced as fatty acids are and consequently not as energy rich 
however glycogen is an important fuel reserve for several reasons. The controlled breakdown 
of glycogen and release of glucose increase the amount of glucose that is available between 
meals. Hence, glycogen serves as a buffer to maintain blood-glucose levels. Glycogen's role 
in maintaining blood-glucose levels is especially important because glucose is virtually the 
only fuel used by the brain, except during prolonged starvation. Moreover, the glucose from 
glycogen is readily mobilized and is therefore a good source of energy for sudden, strenuous 
activity. Unlike fatty acids, the released glucose can provide energy in the absence of oxygen 
and can thus supply energy for anaerobic activity. With the liver serving as a major site of 
glycogen storage, Fenugreek seed extract is more efficient than insulin and metformin in 
allowing for the storage of glycogen via the up-regulation of GS (Figure 27). Resulting in the 
maintenance of blood-glucose levels as required to meet the needs of the organism as a 
whole. 
Phosphorylated sugar molecules do not readily penetrate cell membranes, because there are 
no specific trans-membrane carriers for these compounds, and since they are too polar to 
diffuse through the lipid core of membranes (Francini et al. 2011). The irreversible 
phosphorylation of glucose, therefore, effectively traps the sugar as cytosolic glucose 6-
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phosphate (G-6-P), consequently committing it to further metabolism in the cell (Francini et 
al. 2011; Matschinsky and Sweet 1996). Mammals have several isozymes of the enzyme 
hexokinase (HK) that catalyze the phosphorylation of glucose to G-6-P. In most tissues, the 
phosphorylation of glucose is catalyzed by HK, one of three regulatory enzymes of 
glycolysis. Hexokinase has broad substrate specificity and is able to phosphorylate several 
hexoses in addition to glucose. Hexokinase is inhibited by the reaction product, G-6-P, which 
accumulates when further metabolism of this hexose phosphate is reduced. Hexokinase has a 
low Km (and high affinity) for glucose (Francini et al. 2011). This permits the efficient 
phosphorylation and subsequent metabolism of glucose even when tissue concentrations of 
glucose are low. Hexokinase, however, has a low Vmax for glucose and, therefore, cannot 
sequester cellular phosphate in the form of phosphorylated hexoses, or phosphorylate more 
sugars than the cell can use (Francini et al. 2011).  
In liver parenchymal cells and beta cells of the pancreas, GK (also called HK D, or type IV) 
is the predominant enzyme responsible for the phosphorylation of glucose. In beta cells, GK 
functions as the glucose sensor, determining the threshold for insulin secretion (Francini et al. 
2011). In the liver, the enzyme facilitates glucose phosphorylation during hyperglycaemia. 
Like HK, GK catalyzes the ATP-dependent phosphorylation of glucose to form G-6-P and 
ADP. This is the first step of glycolysis. The enzyme will act on a variety of 6-carbon sugars, 
producing moieties phosphorylated at position six. Glucokinase differs from HK in several 
important properties.  For example, it has a much higher Km (10mM vs. 1mM), requiring a 
higher glucose concentration for half-saturation (Francini et al. 2011). The higher Km for GK 
means that less glucose will be phosphorylated, allowing more glucose to be exported to the 
bloodstream, where it can be delivered to other tissues that do not make their own glucose 
(Cárdenas 1995). Also, GK is not inhibited by G-6-P therefore glucose can be shunted into 
glycogen synthesis. Hence the activity of GK is increased when blood-glucose concentrations 
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are high. Similarly, insulin release is dependent on GK in pancreatic beta cells. Thus, GK 
functions only when the intracellular concentration of glucose in the hepatocyte is elevated, 
such as during the brief period following consumption of a carbohydrate-rich meal, when 
high levels of glucose are delivered to the liver via the portal vein. Glucokinase has a high 
Vmax, allowing the liver to effectively remove the flood of glucose delivered by the portal 
blood (Francini et al. 2011). This prevents large amounts of glucose from entering the 
systemic circulation following a carbohydrate-rich meal, and thus minimizes hyperglycaemia 
during the absorptive period (Francini et al. 2011). Glucose receptor 2 ensures that blood 
glucose equilibrates rapidly across the membrane of the hepatocyte. Glucokinase activity 
rises and falls with available glucose (Buhler et al. 1995; Cheatham et al. 2005). Concomitant 
rise of insulin, amplifies this effect by induction of GK synthesis (Buhler et al. 1995; 
Cheatham and Kahn 2005). 
Fenugreek seed extract caused an elevation in GK activity by 3.99 fold (normoglycaemic) 
and 23.92 fold (hyperglycaemic) (Figure 28). However, under normoglycaemic conditions 4-
OH-lle (0.19 fold), insulin (0.23 fold) and metformin (0.86 fold) reduced the expression but 
under hyperglycaemic conditions 4-OH-lle (2.11 fold), insulin (15.86 fold) and metformin 
(3.36 fold) increased the expression of GK (Figure 28). Fenugreek seed extract effectively 
up-regulated the activity of GK, under both conditions. Fenugreek was as successful or if not 
more successful in controlling hyperglycaemia as compared to insulin and metformin. 
Fenugreek seed extract has displayed its effect efficiently by regulating glycogen synthesis 
via GSK-3α/β and regulating the expression of GK.   
Increased circulating blood glucose requires entry into the cell, in order to efficiently utilize 
the glucose for metabolic activity and storage and ultimately reduce blood glucose levels 
(Ahn et al. 2005; Enjoji et al. 2008). Entry into the cell requires the transcriptional activation 
of GLUT2 via SREBP1c (Ahn et al. 2005; Enjoji et al. 2008). Glucose transporter 2 has a 
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high capacity for glucose but low affinity thus serving as an efficient carrier for blood 
glucose in the liver (Ahn et al. 2005). Insulin activates the hepatic expression of SREBP1c 
(Enjoji et al. 2008). Sterol regulatory element binding protein 1c plays a key role in glucose 
stimulated GLUT2 gene expression (Enjoji et al. 2007). The GLUT2 promoter region is 
activated by SREBP1c (Enjoji et al. 2008, Caro et al. 1987). Fenugreek seed extract up-
regulated the expression of SREBP1c 2.36-fold (normoglycaemic) and 5.03-fold 
(hyperglycaemic) (figure 25). This correlated with the increase in GLUT2 expression 3.79-
fold (normoglycaemic) and 9.87-fold (hyperglycaemic) (figure 26). 4-Hydroxyisoleucine 
reduced the expression of SREBP1c 0.82-fold (normoglycaemic) and 0.9-fold 
(hyperglycaemic) (figure 25). Whereas the expression of GLUT2 is slightly up-regulated 
1.37-fold (normoglycaemic) and 2-fold (hyperglycaemic) (figure 26). Insulin increased the 
expression of SREBP1c 2.09-fold (normoglycaemic) and 3.91-fold (hyperglycaemic) (figure 
25). The expression of GLUT2 was up-regulated 1.5-fold (normoglycaemic) and 2.4-fold 
(normoglycaemic) (figure 26). Sterol regulatory element binding protein 1c was decreased 
0.03-fold (normoglycaemic) and 0.91-fold (hyperglycaemic) by metformin (figure 25).  
Accompanied by a decrease in GLUT2 expression, 0.19 (normoglycaemic) and 0.64 
(hyperglycaemic) fold were observed (figure 246). Fenugreek seed extract displayed a greater 
ability in increasing the expression of GLUT2 following SREBP1c, than insulin – which is 
the cells natural response to increased glucose and metformin – a first line choice of drug for 
the treatment of T2DM. This would be beneficial to the cell, allowing maximum clearance of 
glucose from circulation, into storage, therefore effectively reducing the increased circulating 
blood glucose.  
In T2DM the post-prandial glucose level is approximately 9mMol/l. Under a hyperglycaemic 
state, 100ng/ml insulin reduced the level of glucose by 50% (table 1). Whereas FSE reduced 
the glucose concentrations by 46% (table 1). In comparison to in vivo studies, the use of 
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40ng/ml and 10ng/ml insulin displayed significant reductions in glucose levels (Cignarelli et 
al. 2006; Bolder et al. 2008). When analyzing insulin and FSE these treatments did not bring 
the levels back to normal, however a decrease was noted. When comparing our study to in 
vivo studies, the concentration used is double the current treatment concentration. Therefore 
one can conclude that an increase in the treatment concentration used could effectively 
reduce increased glucose levels back to or near normal.   
Metformin is the first line drug of choice for treatment of T2DM. It has been effective in its 
treatment via the control of energy homeostasis (Pearson et al. 2013; Viollet and Foretz 
2013). In our study, FSE and 4-OH-lle has effectively caused an increase in IR-β, Akt and 
GSK-3α/β protein expression, under both normoglycaemic and hyperglycaemic conditions. 
The genes imperative in the metabolism of glucose – SREBP1c, GLUT2, GS and GK were 
significantly up-regulated under both conditions by FSE and 4-OH-lle greater than 
metformin. It can be concluded that FSE and 4-OH-lle has successfully accomplished its role 
in glucose metabolism by contending with metformin, the common drug used for the 
treatment of T2DM. 
 
Insulin is the natural regulator of glucose. A rise in glucose is required for the release of 
insulin. A low insulin level predisposes the cell to reduced glucose availability, producing an 
extracellular hyperglycaemic state. Hyperglycaemia is characteristic of T2DM caused by 
insulin resistance. Our data strongly suggests the mechanism of action of FSE is similar to or 
even better than that of insulin and metformin. Fenugreek seed extract effectively and 
efficiently displayed its glucose lowering effect by increasing IR-β and phosphorylation of 







Natural herbal products have been and are still a major source in supporting the primary 
health care systems. Their activity is mainly associated with biologically active compounds 
present within the plant. Some of these active compounds aid in the treatment of diseases 
which is overwhelming the population, such as diabetes mellitus. Therefore many plants are 
targets for drug prospecting diabetic - associated programs.  Fenugreek is a source of a group 
of active compounds where 4-OH-lle has been labelled as the most effective in combating 
hyperglycaemia – a chronic symptom in T2DM.  
 
Fenugreek seed extract and 4-OH-lle have displayed their effects at effectively reducing 
important proteins and genes involved in the metabolism of glucose. Their effect has shown 
to be greater than that of the natural glucose reducer – insulin and the common drug – 
metformin. Therefore fenugreek possesses great potential in combating the high-blood 
glucose present in T2DM. However the lack in substantial scientific data regarding the use of 
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Figure 1: Calibration curve using known concentrations of BSA for the determination 
of protein concentration in samples using BCA assay. 
 
 
